Kovalyk, Xenia ORCID: 0009-0006-4143-5686, Saniternik, Sven ORCID: 0009-0009-3027-8322, Hamacher, Larissa-M. ORCID: 0009-0004-9382-5251, Mink, Ben Lasse, Thoröe-Boveleth, Sven, Bach, Patricia ORCID: 0009-0002-4372-1791, Endres, Thomas, Montero-Mirabet, Maria, Schmidt, Annette M. ORCID: 0000-0002-7284-7847 and Grüll, Holger ORCID: 0000-0002-0993-9300 (2026). Gelatin and collagen-mimetic nanoparticles for intraperitoneal cisplatin delivery: From synthesis to in-vivo SPECT imaging of biodistribution. Biomaterials Advances, 180. pp. 1-12. Elsevier. ISSN 2772-9508

[thumbnail of 1-s2.0-S2772950825004285-main.pdf] PDF
1-s2.0-S2772950825004285-main.pdf
Bereitstellung unter der CC-Lizenz: Creative Commons Attribution.

Download (7MB)
Identification Number:10.1016/j.bioadv.2025.214601

Abstract

[Artikel-Nr.: 214601] Peritoneal carcinomatosis is a metastatic condition with poor prognosis, commonly associated with abdominal cancers. Current treatments comprise cytoreductive surgery with systemic chemotherapy or may include more invasive options such as hyperthermic intraperitoneal chemotherapy, and pressurized intraperitoneal aerosol chemotherapy. However, currently, all treatment options are considered palliative as remaining cancer cells cause recurrence. This study explores new intraperitoneal drug delivery systems based on gelatin-poly(glutamic acid) (Gel-PGA-NPs) or collagen-like-peptide-poly(glutamic acid) nanoparticles (CLP-PGA-NPs) loaded with cisplatin for localized treatment of peritoneal carcinomatosis. These NPs, synthesized via in situ polymerization, offer prolonged drug release and continuous biodegradation. The used CLP is produced by a recombinant manufacturing method avoiding any animal-derived material, which has advantages in regard to biocompatibility and reproducibility. Characterization by dynamic light scattering and transmission electron microscopy showed NPs averaging 150 nm in size. Cisplatin loading in CLP-PGA NPs facilitated high drug loading and stability compared to Gel-PGA NPs. SPECT/CT imaging of radiolabeled NPs in healthy mice revealed primary uptake in the spleen and liver, and further accumulation in the pancreas, ovaries and adherence to abdominal tissues highlighting the potential use for treatment of intraperitoneal metastases.

Item Type: Article
Creators:
Creators
Email
ORCID
ORCID Put Code
Kovalyk, Xenia
UNSPECIFIED
UNSPECIFIED
Saniternik, Sven
UNSPECIFIED
UNSPECIFIED
Hamacher, Larissa-M.
UNSPECIFIED
UNSPECIFIED
Mink, Ben Lasse
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Thoröe-Boveleth, Sven
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Bach, Patricia
UNSPECIFIED
UNSPECIFIED
Endres, Thomas
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Montero-Mirabet, Maria
UNSPECIFIED
UNSPECIFIED
UNSPECIFIED
Schmidt, Annette M.
UNSPECIFIED
UNSPECIFIED
Grüll, Holger
UNSPECIFIED
UNSPECIFIED
URN: urn:nbn:de:hbz:38-812741
Identification Number: 10.1016/j.bioadv.2025.214601
Journal or Publication Title: Biomaterials Advances
Volume: 180
Page Range: pp. 1-12
Number of Pages: 12
Date: March 2026
Publisher: Elsevier
ISSN: 2772-9508
Language: English
Faculty: Faculty of Mathematics and Natural Sciences
Faculty of Medicine
Divisions: Faculty of Mathematics and Natural Sciences > Department of Chemistry > Institute of Biochemistry
Faculty of Medicine > Experimentelle Medizin > Institut für Experimentelle Medizin
Faculty of Medicine > Radiologische Diagnostik > Institut und Poliklinik für Radiologische Diagnostik
Subjects: Chemistry and allied sciences
Life sciences
Medical sciences Medicine
['eprint_fieldname_oa_funders' not defined]: Publikationsfonds UzK
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/81274

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item